Last updated: July 4, 2026
Novartis Pharmaceuticals Corporation v. Apotex Inc., case number 1:18-cv-01038, is a U.S. Hatch-Waxman patent infringement dispute filed in 2018. The docket number is identified, but no court filings, asserted patents, claim constructions, deadlines, infringement/invalidity theories, Markman outcomes, settlement terms, or final disposition are available in the information provided. Without those case-specific records, a complete and accurate litigation summary and analysis cannot be produced.
What patents were asserted in Novartis v. Apotex 1:18-cv-01038?
No asserted-patent list (Orange Book patents, asserted claim numbers, or amendment history) is available from the provided input. A litigation analysis that ties the case to specific patent claims, expiration dates, and infringement/invalidity arguments cannot be completed.
Which Orange Book-listed patents were included?
No Orange Book listing, patent numbers, or FDA product link is present in the provided input.
What claim types were at issue (composition, formulation, method-of-use, manufacturing)?
No asserted claim categories or independent claim themes are available from the provided input.
What is the procedural timeline for 1:18-cv-01038 (filing, answers, Markman, motions, trial, judgment)?
A litigation timeline requires docket events (complaint filing date, service date, answer, Rule 12 motions, infringement contentions, invalidity contentions, Markman scheduling, summary judgment briefing, trial or consent judgment, and any post-judgment orders). None of these dates or event descriptors are available in the provided input.
When was the complaint filed and when did Apotex respond?
No complaint filing date or responsive pleading date is available in the provided input.
Were there PTAB IPRs or parallel proceedings?
No IPR/CBM/related PTAB outcomes are available in the provided input.
How strong were Novartis’s infringement theories in 1:18-cv-01038?
Infringement strength requires the asserted claim construction, mapping to the accused product(s), expert declarations, and any admissions or factual stipulations. None of these materials are available in the provided input.
Which accused product(s) did Apotex manufacture or seek to market?
No drug name, NDC, dosage form, strength, or FDA application identifier is available in the provided input.
What did Novartis argue about the accused manufacturing process or formulation?
No process/formulation allegations are available in the provided input.
What invalidity defenses did Apotex raise in 1:18-cv-01038?
Invalidity analysis requires the specific defenses asserted in pleadings and briefed (anticipation, obviousness, lack of written description/enablement, indefiniteness, statutory subject matter, improper inventorship, prosecution history estoppel) plus the cited references. None of these details are present in the provided input.
Which prior art references were used?
No prior-art citations are available in the provided input.
Did the court address obviousness, anticipation, or §112 issues?
No claim-level invalidity rulings or reasoning are available in the provided input.
What did claim construction decide, and how did that affect outcomes?
Claim construction requires the Markman order and the construed limitations, plus subsequent effects on infringement and invalidity. No Markman record is available in the provided input.
Was any claim construction outcome dispositive?
No dispositive rulings are available in the provided input.
Did the case settle, and what were the settlement terms or effective launch date constraints?
Settlement analysis requires the settlement agreement or docketed order (stipulation of dismissal, consent judgment, prohibition period, covenant-not-to-sue scope, launch and supply constraints, design-around permissions, royalty or license terms, and confidentiality carve-outs). None of these are available in the provided input.
Was there a dismissal with prejudice or without prejudice?
No disposition status is available in the provided input.
Did Apotex receive an agreed launch window or carve-out?
No settlement terms are available in the provided input.
How does 1:18-cv-01038 affect potential generic entry and FDA approval timing?
FDA timing impact depends on the specific Orange Book patents involved, any statutory exclusivity, the effective date of any settlement order, and the litigation outcome. Those inputs are not provided.
When do the relevant patents expire?
No patent expiration dates are available in the provided input.
What is the Paragraph IV risk profile from this case?
No Paragraph IV certification details (underlying FDA application, patent list challenged, and certification paragraph) are available in the provided input.
Which companies were involved on the litigation side (Novartis entities, Apotex entities, and counsel)?
A complete litigation summary requires identification of the correct corporate parties, subsidiaries, and counsel appearances. None of that is provided in the input.
Were there co-defendants or additional parties?
No party list is available in the provided input.
Key takeaways
- Case identification is known: Novartis Pharmaceuticals Corporation v. Apotex Inc., 1:18-cv-01038.
- Case-specific substance needed for a litigation summary (asserted patents, accused product, claim constructions, motions, rulings, or settlement/judgment) is not present in the provided information.
- No analysis of infringement strength, invalidity defenses, or generic entry timing can be produced without the docket record and patent assertions.
FAQs
- What is the court and district for 1:18-cv-01038?
- Which Orange Book patents does the case challenge in the Hatch-Waxman framework?
- What claim construction did the court issue in Novartis v. Apotex 1:18-cv-01038?
- Did Novartis and Apotex reach a settlement, and what launch restrictions were imposed?
- How would the outcome of 1:18-cv-01038 affect FDA approval and potential generic launch timing?
References
- (No citable case documents, docket entries, or filings were provided in the input.)
